- Home
- MIRM vs FROG Comparison
MIRM vs FROG Comparison
Compare MIRM & FROG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | FROG |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.9B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIRM | FROG |
|---|---|---|
| Price | $106.24 | $67.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 20 |
| Target Price | ★ $119.85 | $65.75 |
| AVG Volume (30 Days) | 667.9K | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | 1.59 |
| EPS | N/A | ★ N/A |
| Revenue | $19,138,000.00 | ★ $531,840,000.00 |
| Revenue This Year | $26.22 | $20.37 |
| Revenue Next Year | $22.04 | $16.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.12 |
| 52 Week Low | $42.89 | $34.05 |
| 52 Week High | $112.00 | $72.06 |
Technical Indicators
Market Signals| Indicator | MIRM | FROG |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 76.11 |
| Support Level | $87.26 | $55.65 |
| Resistance Level | $107.51 | $70.43 |
| Average True Range (ATR) | 5.87 | 3.23 |
| MACD | 0.98 | 2.41 |
| Stochastic Oscillator | 75.13 | 84.45 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from united states and also has its presence in Israel, India and other regions.